Eka.Care Partners with Major Hospitals to Expand Services

GSK’s Blujepa (gepotidacin) has received FDA approval for the treatment of uncomplicated urinary tract infections (uUTIs) in females aged 12 and above (≥40 kg). This marks the first approval in a new class of oral antibiotics for uUTIs in nearly three decades, targeting an urgent public health need amidst rising antimicrobial resistance.

‍Lorundrostat, a novel aldosterone synthase inhibitor developed by Mineralys Therapeutics, has demonstrated significant blood pressure reductions in two pivotal hypertension trials, according to the company’s announcement. The drug targets uncontrolled and resistant hypertension, which affects approximately 20 million people in the U.S. alone.

Five students from classes 1 and 2 at St. Paul’s International School, Kalamassery, in Kerala’s Ernakulam district have been hospitalized after exhibiting symptoms consistent with viral meningitis, raising alarms among health authorities.